A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis
Latest Information Update: 21 Jun 2024
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Lisaftoclax (Primary) ; Pomalidomide (Primary)
- Indications Amyloidosis; Multiple myeloma
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 18 Jun 2024 According to Ascentage pharma media release, updated data from this study presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain.
- 18 Jun 2024 Results published in the Ascentage Pharma Media Release
- 12 Dec 2023 Results (n=30) evaluating lisaftoclax combined with pomalidomide and dexamethasone (Arms A and C) or daratumumab, lenalidomide, and dexamethasone (Arm B) in patients with R/R MM (Arm A and B) or R/R amyloidosis (Arm C), presented at the 65th American Society of Hematology Annual Meeting and Exposition